Cancer Res Treat.  2018 Oct;50(4):1331-1342. 10.4143/crt.2017.466.

High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In vivo Compared with Monotherapy

• Lee JE
• Lim JH
• Hong YK
• Yang SH

• KMID: 2424805
• DOI: http://doi.org/10.4143/crt.2017.466

Abstract

PURPOSE
The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in Vitro and in vivo.
MATERIALS AND METHODS
We investigated the efficacy of combined treatment with TMZ and metformin using cell viability and apoptosis assays. A GBM orthotopic mice model was established by inoculation of 5×105 U87 cells and treatedwith metformin, TMZ, and the combination for 4weeks. Western blotting and immunofluorescence of tumor specimens were analyzed to investigate AMP-activated protein kinase (AMPK) and AKT pathway.
RESULTS
The combination of TMZ and metformin showed higher cytotoxicity than single agents in U87, U251, and A172 cell lines. A combination of high-dose metformin and TMZ showed the highest apoptotic activity. The combination of TMZ and metformin enhanced AMPK phosphorylation and inhibited mammalian target of rapamycin phosphorylation, AKT phosphorylation, and p53 expression. The median survival of each group was 43.6, 55.2, 53.2, 65.2, and 71.3 days for control, metformin treatment (2 mg/25 g/day or 10 mg/25 g/day), TMZ treatment (15 mg/kg/day), combination treatment with low-dose metformin and TMZ, and combination treatment with high-dose metformin and TMZ, respectively. Expression of fatty acid synthase (FASN) was significantly decreased in tumor specimens treated with metformin and TMZ.
CONCLUSION
The combination of metformin and TMZ was superior to monotherapy using metformin or TMZ in terms of cell viability in Vitro and survival in vivo. The combination of high-dose metformin and TMZ inhibited FASN expression in an orthotopic model. Inhibition of FASN might be a potential therapeutic target of GBM.

Keyword

Glioblastoma; Metformin; Temozolomide; Fatty acid synthase

MeSH Terms

AMP-Activated Protein Kinases
Animals
Apoptosis
Blotting, Western
Cell Line
Cell Survival
Fluorescent Antibody Technique
Glioblastoma*
In Vitro Techniques*
Metformin*
Mice
Phosphorylation
Sirolimus
AMP-Activated Protein Kinases
Metformin
Sirolimus

Figure

• 

  Fig. 1. The cytotoxic effects of metformin (Met) and temozolomide (TMZ) on U87 (A), U251 (B), and A172 (C) cell lines. Cell viability was measured by MTT assay and cell viability (percentage) was determined by normalizing each group to the control. Values are presented as mean±standard error of mean (n=3). *p < 0.05.

• 

  Fig. 2. Flow cytometry analysis of apoptosis and necrosis. The high-dose combination of metformin (Met; 20 mM) and temozolomide (TMZ; 500 μM) showed the highest apoptotic activity.

• 

  Fig. 3. Combined treatment with metformin (Met) and temozolomide (TMZ) enhanced AMP-activated protein kinase (AMPK) phosphorylation and inhibited mammalian target of rapamycin (mTOR) phosphorylation, AKT phosphorylation, and p53 expression. PBS, phosphate buffered saline.

• 

  Fig. 4. Survival of orthotopic mice is represented in a Kaplan-Meier plot. Met, metformin; TMZ, temozolomide.

• 

  Fig. 5. (A) AMP-activated protein kinase (AMPK) immunohistochemistry showed strong positivity in tumor specimens treated with a combination of metformin (Met) and temozolomide (TMZ) (×200). Similarly, high immunofluorescence showed that the combined treatment increased nuclear accumulation of phosphorylated AMPK (p-AMPK). (B) 4',6- Diamidino-2-phenylindole (DAPI) staining was used to determine nuclear localization (×200).

• 

  Fig. 6. Western blot analysis showed inhibition of fatty acid synthase (FASN) expression after combined treatment with high-dose metformin (Met) and temozolomide (TMZ).

Reference

References

1. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol. 2011; 67:971–83.

2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987–96.

3. Di Cristofori A, Carrabba G, Lanfranchi G, Menghetti C, Rampini P, Caroli M. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res. 2013; 33:3383–9.

4. Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res. 2013; 33:3487–94.

5. Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, et al. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro Oncol. 2016; 18:991–1001.

6. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69:7507–11.

7. Gou S, Cui P, Li X, Shi P, Liu T, Wang C. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013; 8:e63969.

8. Nangia-Makker P, Yu Y, Vasudevan A, Farhana L, Rajendra SG, Levi E, et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One. 2014; 9:e84369.

9. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK, et al. Metformin targets ovarian cancer stem cells in Vitro and in vivo. Gynecol Oncol. 2012; 127:390–7.

10. Yu Z, Zhao G, Li P, Li Y, Zhou G, Chen Y, et al. Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stem-like cells. Oncol Lett. 2016; 11:2792–800.

11. Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, et al. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in Vitro and in vivo. Oncotarget. 2015; 6:32930–43.

12. Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemarie A, et al. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS One. 2015; 10:e0123721.

13. Bosi E. Metformin: the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab. 2009; 11 Suppl 2:3–8.

14. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther. 2013; 12:1605–15.

15. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016; 7:27–31.

16. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015; 16:839–47.

17. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry. 1989; 28:4523–30.

18. Seguin F, Carvalho MA, Bastos DC, Agostini M, Zecchin KG, Alvarez-Flores MP, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br J Cancer. 2012; 107:977–87.

19. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012; 72:1504–17.

20. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7:763–77.

21. Grube S, Dunisch P, Freitag D, Klausnitzer M, Sakr Y, Walter J, et al. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis. J Neurooncol. 2014; 118:277–87.

22. Zhou Y, Jin G, Mi R, Zhang J, Zhang J, Xu H, et al. Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma. J Cancer Res Clin Oncol. 2016; 142:2447–59.

23. Yasumoto Y, Miyazaki H, Vaidyan LK, Kagawa Y, Ebrahimi M, Yamamoto Y, et al. Inhibition of fatty acid synthase decreases expression of stemness markers in glioma stem cells. PLoS One. 2016; 11:e0147717.

24. Yang SH, Li S, Lu G, Xue H, Kim DH, Zhu JJ, et al. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Oncotarget. 2016; 7:78787–803.